Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population

被引:8
|
作者
Mutawi, Thuraya M. [1 ]
Zedan, Mohamed M. [2 ]
Yahya, Raida S. [1 ]
Zakria, Mahmoud M. [3 ]
El-Sawi, Mamdouh R. [4 ]
Gaedigk, Andrea [5 ,6 ]
机构
[1] Mansoura Univ, Children Hosp, Dept Labs, Fac Med, Mansoura 35516, Egypt
[2] Mansoura Univ, Dept Pediat, Fac Med, Mansoura 35516, Egypt
[3] Mansoura Univ, Urol & Nephrol Ctr, Fac Sci, Mansoura 35516, Egypt
[4] Mansoura Univ, Div Physiol, Dept Zool, Fac Sci, Mansoura 35516, Egypt
[5] Univ Missouri Kansas City, Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[6] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64108 USA
关键词
genotype; phenotype Egyptian population; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; HUMAN CYTOCHROME-P450 2D6; POOR METABOLIZERS; CPIC GUIDELINE; CYP3A4-ASTERISK-22; POLYMORPHISMS; ALLELES; DUPLICATION; PHENOTYPE; VARIANTS;
D O I
10.2217/pgs-2020-0140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: This study investigated major allelic variants of CYP2D6, CYP3A4 and CYP3A5 in Egyptians, an Arabic population for which there is little information regarding these important pharmacogenes. Patients & methods: CYP2D6*2, *4, *5, *10, *41 and gene copy number variation, as well as CYP3A4*22 and CYP3A5*3 were determined with commercially available TaqMan assays in 145 healthy study participants. Results: The CYP2D6 alleles identified suggest that the prevalence of poor metabolizers is low as none were found among the 145 subjects investigated. The frequency for CYP3A5 nonexpressers was 74.5% and the CYP3A4*22 allele frequency was low at 2.0%. Conclusion: These preliminary findings indicate that pharmacogene variation in Egyptians is different from those of other Middle Eastern/Arabic populations and warrants further investigation.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 50 条
  • [31] Development of CYP2D6 and CYP3A4 in the first year of life
    Johnson, T. N.
    Tucker, G. T.
    Rostami-Hodjegan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) : 670 - 671
  • [32] CYP2D6, CYP2C19, CYP2C9 and CYP3A5 polymorphism in the Spanish population
    Llovo, R.
    Tudoli, I
    Carril, J. C.
    Fernandez-Novoa, L.
    Seoane, S.
    Cacabelos, R.
    NEW TRENDS IN ALZHEIMER AND PARKINSON RELATED DISORDERS: ADPD 2009, 2009, : 53 - 57
  • [33] Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
    Maslub, Mohammed G.
    Radwan, Mahasen A.
    Daud, Nur Aizati Athirah
    Sha'aban, Abubakar
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [34] Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?
    Mohammed G. Maslub
    Mahasen A. Radwan
    Nur Aizati Athirah Daud
    Abubakar Sha’aban
    European Journal of Medical Research, 28
  • [35] Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
    Williams, JA
    Ring, BJ
    Cantrell, VE
    Jones, DR
    Eckstein, J
    Ruterbories, K
    Hamman, MA
    Hall, SD
    Wrighton, SA
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (08) : 883 - 891
  • [36] Genetic polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2D6, and CYP3A4 in the Turkish population
    Semiz, A.
    Aynaci, H. K.
    Kus, E.
    Elmas, L.
    Sen, A.
    FEBS JOURNAL, 2008, 275 : 110 - 110
  • [37] CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population
    Hu, YF
    He, J
    Chen, GL
    Wang, D
    Liu, ZQ
    Zhang, C
    Duan, LF
    Zhou, HH
    CLINICA CHIMICA ACTA, 2005, 353 (1-2) : 187 - 192
  • [38] Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities
    Kwok, Wang Chun
    Lam, David Chi Leung
    Ip, Mary Sau Man
    Tam, Terence Chi Chun
    Ho, James Chung Man
    ANTI-CANCER DRUGS, 2022, 33 (10) : 1139 - 1144
  • [39] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
  • [40] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13